Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2024-01-02 00:00:00 ET · period of report 2023-12-28 · accession 0001209191-24-000255 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-02 | 2023-12-28+ | ELVN | Hohl Benjamin | CFO | M - OptEx | $2.48 | +11.9K | 9,383 | New | +$29.4K |
| DM | 2024-01-02 | 2023-12-28+ | ELVN | Hohl Benjamin | CFO | S - Sale+OE | $15.02 | -11.9K | 0 | -100% | -$178.3K |
| DM | 2024-01-02 | 2023-12-28+ | ELVN | Hohl Benjamin | CFO | M - OptEx | $0.00 | -11.9K | 249.1K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-29 | M | A | 20 | $2.48 | 20 | D | — | — | |
| 2 | Common | Common Stock | 2023-12-28 | S | D | 2,467 | $15.07 | 0 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $15.00 to $15.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 3 | Common | Common Stock | 2023-12-28 | M | A | 2,467 | $2.48 | 2,467 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-29 | S | D | 20 | $15.00 | 0 | D | — | — | |
| 5 | Common | Common Stock | 2024-01-02 | M | A | 9,383 | $2.48 | 9,383 | D | — | — | |
| 6 | Common | Common Stock | 2024-01-02 | S | D | 9,383 | $15.01 | 0 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $15.00 to $15.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 7 | Derivative | Employee Stock Option (right to buy) | 2023-12-28 | M | D | 2,467 | $0.00 | 258,523 | D | $2.48 · — to 2031-08-02 | 2,467 Common Stock | (F4) The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. |
| 8 | Derivative | Employee Stock Option (right to buy) | 2023-12-29 | M | D | 20 | $0.00 | 258,503 | D | $2.48 · — to 2031-08-02 | 20 Common Stock | (F4) The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. |
| 9 | Derivative | Employee Stock Option (right to buy) | 2024-01-02 | M | D | 9,383 | $0.00 | 249,120 | D | $2.48 · — to 2031-08-02 | 9,383 Common Stock | (F4) The option, originally for 262,120 shares, vested as to one-fourth of the shares vests on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter. |